Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.
By Manuela Bianco Suarez University of Kentucky Healthcare This winter, low temperatures have impacted the state of Kentucky. One of the biggest concerns statewide is the rise in the number of ...